Abstract
Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 327-333 |
| Number of pages | 7 |
| Journal | European Urology, Supplements |
| Volume | 6 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2007 |
Fingerprint
Keywords
- Prostate cancer
- PSA
- PSA doubling time
- PSA velocity
ASJC Scopus subject areas
- Urology
Cite this
The Continuing Role of PSA in the Detection and Management of Prostate Cancer{A figure is presented}. / Miller, Kurt; Abrahamsson, Per Anders; Akakura, Koichiro; Debruyne, Frans M J; Evans, Christopher P; Klotz, Laurence.
In: European Urology, Supplements, Vol. 6, No. 3, 03.2007, p. 327-333.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The Continuing Role of PSA in the Detection and Management of Prostate Cancer{A figure is presented}
AU - Miller, Kurt
AU - Abrahamsson, Per Anders
AU - Akakura, Koichiro
AU - Debruyne, Frans M J
AU - Evans, Christopher P
AU - Klotz, Laurence
PY - 2007/3
Y1 - 2007/3
N2 - Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy.
AB - Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy.
KW - Prostate cancer
KW - PSA
KW - PSA doubling time
KW - PSA velocity
UR - http://www.scopus.com/inward/record.url?scp=33846408703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846408703&partnerID=8YFLogxK
U2 - 10.1016/j.eursup.2006.12.001
DO - 10.1016/j.eursup.2006.12.001
M3 - Article
AN - SCOPUS:33846408703
VL - 6
SP - 327
EP - 333
JO - European Urology, Supplements
JF - European Urology, Supplements
SN - 1569-9056
IS - 3
ER -